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Severe mental illness and substance use disorders in 
prisoners in low-income and middle-income countries: 
a systematic review and meta-analysis of prevalence studies
Gergő Baranyi, Carolin Scholl, Seena Fazel, Vikram Patel, Stefan Priebe, Adrian P Mundt
Summary
Background Although more than two thirds of the world’s incarcerated individuals are based in low-income and 
middle-income countries (LMICs), the burden of psychiatric disorders in this population is not known. This review 
provides estimates for the prevalence of severe mental illness and substance use disorders in incarcerated individuals 
in LMICs.
Methods For this systematic review and meta-analysis, we searched 17 electronic databases to identify prevalence 
studies of psychiatric disorders in prison populations in LMICs, published between January, 1987, and May, 2018. We 
included representative studies from general prison samples, providing information about four major psychiatric 
diagnoses: psychosis, major depression, alcohol use disorders, and drug use disorders. We pooled data from studies 
using random-effects meta-analyses and assessed the sources of heterogeneity by meta-regression. We extracted 
general population estimates from the Global Burden of Diseases 2016 database to calculate comparative prevalence 
ratios. This study is registered with PROSPERO, number CRD42015020905.
Findings We identified 23 publications reporting prevalence estimates of severe mental illness and substance use 
disorders for 14 527 prisoners from 13 LMICs. In this population, the estimated pooled 1 year prevalence rates for 
psychosis were 6·2% (95% CI 4·0–8·6), 16·0% (11·7–20·8) for major depression, 3·8% (1·2–7·6) for alcohol use 
disorders, and 5·1% (2·9–7·8) for drug use disorders. We noted increased prevalence at prison intake and geographic 
variations for substance use disorders. For alcohol use disorders, prevalence was higher in the southeast Asian region 
than in the eastern Mediterranean region; and drug use disorders were more prevalent in the eastern Mediterranean 
region than in Europe. Prevalence ratios indicated substantially higher rates of severe mental illness and substance use 
disorders among prisoners than in the general population (the prevalence of non-affective psychosis was on average 
16 times higher, major depression and illicit drug use disorder prevalence were both six times higher, and prevalence of 
alcohol use disorders was double that of the general population).
Interpretation The prevalence of major psychiatric disorders is high in prisoners in LMIC compared with general 
populations. As these findings are likely to reflect unmet needs, the development of scalable interventions should be 
a public health priority in resource-poor settings.
Funding CONICYT of the Chilean government and the Wellcome Trust.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
More than 7 million prisoners are based in low-income 
and middle-income countries (LMICs), comprising about 
70% of the world’s total prison population.1 Conditions in 
these facilities are usually characterised by overcrowding, 
poor nutri tion, and sanitation, and limited or complete 
lack of access to basic health care, which have raised 
public health and human rights concerns.2,3 However, 
apart from one review in 2012,4 which included only a few 
studies from LMICs, the prevalence of major psychiatric 
disorders is not reliably known.4,5 Over the past 5 years, 
several high-quality prevalence studies have been 
published from LMIC settings.6,7
Mental health and substance use disorders are com-
mon among people involved with the criminal justice 
system.4,8,9 Although prisoners with unmet mental 
health-care needs are at higher risk of suicide attemps,10 
mortality,11 and recidivism after release,12 mental health 
disorders often remain undiagnosed and untreated 
in correctional settings.3,5 Up to now, most research 
on mental health problems in prisoners has focused 
on high-income countries (HICs). Establishing the 
prevalence rates of severe mental illness and substance 
use disorders in LMICs will provide a basis for service 
and policy developments in countries with resource-
poor cor rectional settings.
We aimed to systematically review the literature of 
severe mental illness (psychotic disorders and major 
depression) and substance use disorders (alcohol use 
disorders and illicit drug use disorders) in prison 
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populations in LMICs, to estimate prevalence rates 
and prevalence ratios, and to examine sources of 
heterogeneity.
Methods
This systematic review and meta-analysis was conducted 
in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA).13
Search strategy and selection criteria
We conducted a multistage search to identify relevant 
literature on the prevalence of severe mental illness 
and substance use disorders in prison populations 
from LMICs published between January, 1987, and 
May, 2018. The search strategy comprised a search of 
online databases (ASSIA; CAB Abstracts; CNKI; 
Criminal Justice Database; Embase; Global Health; 
IBSS; LILACS; MEDLINE; NCJRS; PAIS Index; 
PsycINFO; Scopus; Social Services Abstracts) and the 
grey literature (Google Scholar; Open Grey; ProQuest 
Dissertations and Theses Global); screening of 
reference lists of identified papers and relevant reviews; 
and corresponding with authors to gain additional 
information or to clarify data. The appendix provides a 
full list of the search terms used for the online database 
searches. Articles from all languages were included.
We included studies in which the following criteria 
were met: data were collected in general prison 
populations; the sample was representative for the 
population of the assessed correctional facility; the 
study was conducted in a LMIC at the time of data 
collection or maximum 1 year after classification has 
changed; the prevalence of severe mental illness and 
substance use disorders were based on clinical 
examinations or established with validated question-
naires as part of a clinical or research interview; and 
diagnoses met the criteria of international diagnostic 
classifications (Diagnostic and Statistical Manual of 
Mental Disorders [DSM] or International Classification 
of Diseases [ICD]). Studies were excluded when: 
prevalence rates were established in selected subgroups 
of incarcerated individuals (eg, offender type); sampling 
strategy was convenient;14 data originated from a HIC;15 
prevalence was reported based on measures and tools 
that used solely self-report, which did not fulfil 
diagnostic criteria. Finally, conference abstracts and 
duplicates were excluded. Two re searchers (GB and CS) 
screened abstracts and full-texts and disagreements 
between the reviewers were resolved by consensus 
with APM.
Data analysis
Two reviewers (GB and CS) independently extracted year 
and country of data collection, sex, age, type of 
recruitment (from all prisoners or at admission), 
sampling strategy, non-response rate, time served in 
prison, interviewer (mental health professional or 
research assistant), diagnostic classification system 
(DSM or ICD), diagnostic instrument, and number of 
incarcerated individuals, for which 1 year prevalence was 
Research in context
Evidence before this study
Although 70% of incarcerated men and women are residing in 
low-income and middle-income countries, almost all evidence 
on mental disorders among prisoners is based on studies from 
high-income countries, providing implications that are not 
applicable or generalisable to poorly resourced settings. 
The prevalence of psychiatric disorders in the penal justice 
systems of low-income and middle-income countries (LMICs) is 
likely to differ from high-income countries because of the 
scarcity of resources, as well as cultural and legal factors.
To fill this knowledge gap, we systematically searched for 
prison prevalence studies based in LMICs published between 
January, 1987, and May, 2018, in 17 electronic global 
databases, including sources of grey literature. Our search 
terms covered a range of key words and subject headings on 
mental health, prison conditions, and epidemiological 
investigations. We included representative studies from 
general prison samples from LMICs, providing information 
about four major psychiatric diagnoses: psychosis, major 
depression, alcohol use disorders, and drug use disorders, 
published in any language. Our search identified no systematic 
reviews focusing on the context of LMICs.
Added value of this study
We identified 23 studies from 13 countries, most of which had 
not previously been included in reviews. Our analysis 
established the pooled 1 year prevalence rates of four major 
mental illnesses in prisoner populations in LMICs. Furthermore, 
our findings emphasise that on arrival to prisons in LMICs, 
mental disorders may be more prevalent than in samples that 
also represent later stages of imprisonment.
Implications of all the available evidence
In LMICs, the prevalence of psychiatric disorders in prison 
populations is higher than among people living in the 
community. Rates in prison populations of LMICs might be even 
higher than in high-income countries. Because correctional 
facilities often lack basic health care in low-income and 
middle-income economies, the implementation of 
cost-effective interventions and scalable treatments for 
individuals with mental health problems are needed. Since 
human rights violations, and physical and psychological abuse 
are more common in resource-poor correctional settings, 
protecting the rights and health of people with mental illnesses 
should be a priority for penal justice policies.
See Online for appendix
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reported for psychotic illness (ICD-10 codes: F20–F29, 
F31, F32·3, F33·3) and major depression (F32–33, except 
F32·3, F33·3). We extracted both 1 year and lifetime 
prevalence rates of alcohol (F10) and drug use disorders 
(F11–19, except F17). Male and female samples were 
considered separately. Studies that did not report separate 
rates but included less than 10% of the study participants 
of one sex were included as representative for the other 
sex; otherwise they were described as mixed samples. 
When the year of data collection was not reported, we 
imputed a year based on the average mean difference 
between the year of publication and data collection 
derived from the other studies (4 years).9 We prespecified 
categories for sample size (n<500, n≥500) and average 
time served in prison (time <1 year, time ≥1 year). 
Countries were categorised into LMIC and HIC based 
on their per capita Gross National Income, calculated 
with the World Bank’s Atlas method for the year of 
data collection. To examine geo graphic variation of preva-
lence estimates within LMIC, we used WHO regional 
classification. If schizophrenia-spectrum, bipolar dis-
order (which can present with acute psychotic states), 
and psychotic depression were presented separately, we 
combined them, in order to create one estimate for 
overall psychotic disorders. By combining abuse and 
dependence disorders, we produced single rates for 
alcohol and drug use disorders.
To assess methodological quality, two reviewers 
(GB and CS) evaluated the internal and external validity 
of the included samples based on a modified scale of 
ten questions,16 which allowed a critical appraisal of 
prevalence rates in epidemiological investigations 
(appendix).
To account for the heterogeneity between studies, we 
performed random-effects meta-analysis by estimating 
the pooled mean of the distribution.17 For individual 
samples, we first calculated 95% score confidence 
intervals (CIs). Variance of the proportions was stabilised 
with Freeman-Tukey double arcsine transformation 
and pooled together with the DerSimonian and Laird 
method.18 The incon sistency between samples was 
quantified with I².19 As previous prevalence meta-analyses 
reported high between-sample heterogeneity, we also 
provided prevalence ranges.20 Sensitivity analysis was 
conducted pooling 6 month estimates of severe mental 
illness as reported in a review for HIC.4 Pooled rates for 
subgroups were displayed, when at least five samples 
were present.
We conducted random-effects meta-regressions by 
assessing pre-specified sample characteristics on the 
pooled estimate.17 Models in the meta-regression were 
fitted with the restricted maximum likelihood method and 
corrected with the Hartung-Knapp variance estimator.21 To 
test whether lower quality investigations systematically 
distort the pooled estimates, we included the quality score 
of samples as a covariate. Univariate meta-regression 
analysis was performed when at least ten samples were 
available,22 multivariate by 20 or more samples, retaining 
only significant variables (p<0·05).
We calculated prevalence ratios (PR) and their 95% CIs 
to quantify the difference between the prevalence among 
prisoners (p) in each sample and in the sex-matched 
general populations (P) of the respective countries based 
on the following equation23:
We extracted sex-specific and country-specific prevalence 
rates from the Global Burden of Diseases 2016 database for 
the year of data collection in the respective prison survey. 
The matching population size (N) was imputed from the 
2017 Revision of World Population Prospects. Because a 
national reference for psychosis is not available, rates for 
schizophrenia were extracted and matched with prison 
study rates for schizophrenia, if available. If not, we used 
rates of non-affective psychotic illness. Prevalence ratios 
were pooled with random-effects meta-analysis. Sensitivity 
analyses were conducted for studies reporting 6 month 
rates of severe mental illness; and for schizophrenia, 
without imputed values of psychotic disorders.
For the Global Burden of 
Diseases database see 
http://ghdx.healthdata.org/
gbd-results-tool 
For more on the World Bank’s 
Atlas method see https://data.
worldbank.org/
For the 2017 Revision of World 
Population Prospects see 
https://esa.un.org/unpd/wpp/
DataQuery
PR= 
p
P ;SE= √
1
p × n
+ 1
P × N
– 1
n ;
95% CI=eln(PR) ± 1·96 × SE
1
N
–
Figure 1: Study identification, screening and eligibility test, following the Preferred Reporting Items of 
Systematic Reviews (PRISMA) 
DSM=Diagnostic and Statistical Manual of Mental Disorders. ICD=International Classification of Diseases. 
12 720 records identified through database searches 26 records identified through other sources 
5947 records after removal of duplicates 
5823 records excluded
101 articles excluded
 24 did not report prevalence rates of mental 
  health or substance use disorders 
 20 assessed selected study populations
 10 did not have representative sampling 
  methods
 10 were from high-income countries
 22 applied non-standardised instruments 
  that did not meet the diagnostic criteria  
  of DSM or ICD
 8 were conference abstracts or did not 
  report empirical data
 6 were duplicates
 1 full-text was not retrieved
5947 records screened 
124 full-text articles assessed for eligibility
23 studies included in systematic review 
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Biased prevalence estimates might arise not only from 
the inclusion of studies with lower methodological 
quality but also from publication or small study bias.22 To 
assess publication bias, we drew funnel plots presenting 
prev alence estimates against their SEs and tested the 
asymmetry of the funnel plots with Egger’s test,24 when 
ten or more samples were available.
All analyses were done with STATA (version 13). 
This study is registered with PROSPERO, number 
CRD42015020905.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
Country WHO region Sex Sampling Sample 
size
Non-response 
rate (%)
Interviewer Diagnostic 
instrument
Diagnostic 
criteria
Quality 
appraisal score
Adesanya et al38 Nigeria Africa Male Population 395 4·8 Not stated Not stated DSM-III-R 6
Andreoli et al6*† Brazil Americas Male Stratified random 1192 26·8 Trained non-clinician CIDI ICD-10 8
Andreoli et al6*† Brazil Americas Female Stratified random 617 10·5 Trained non-clinician CIDI ICD-10 9
Assadi et al36† Iran Eastern 
Mediterranean
Male Stratified random 351 12·3 Psychiatrist SCID-CV DSM-IV 9
Ayirolimeethal et al31‡ India Southeast Asia Male Population 222 3·5 Psychiatrist MINI-Plus Not stated 8
Ayirolimeethal et al31‡ India Southeast Asia Female Population 33 0·0 Psychiatrist MINI-Plus Not stated 7
Boşgelmez et al44 Turkey Europe Male Stratified random 30 6·3 Psychiatrist, clinical 
psychologist
SCID DSM-IV 7
Boşgelmez et al44 Turkey Europe Female Stratified random 30 11·8 Psychiatrist, clinical 
psychologist
SCID DSM-IV 7
Canazaro and 
Argimon27
Brazil Americas Female Population 287 22·0 Psychology student, 
psychologist
SCID-CV DSM-IV 8
El-Gilany et al30† Egypt Eastern 
Mediterranean
Mixed Stratified random 1350 0·5 Psychiatrist SCID DSM-IV 8
Goyal et al32 India Southeast Asia Male Random 500 Not stated Consultant PSE ICD-10 7
Joshi et al35 India Southeast Asia Female Population 50 Not stated Psychiatrist Not stated DSM-IV TR 6
Kaya et al45*‡ Turkey Europe Male Random 305 14·3 Psychiatric assistant, 
trainee psychiatrist
CIDI DSM-IV 6
Kumar and Daria33 India Southeast Asia Male Random 118 9·2 Psychiatrist IPIS ICD-10 7
Majekodunmi et al39*‡ Nigeria Africa Male Random 196 1·5 Psychiatrist SCID DSM-IV 8
Math et al34† India Southeast Asia Male Population 5024 Not stated Research assistant MINI-Plus Not stated 4
Mundt et al7*‡ Chile Americas Male Random 855 1·0 Field worker CIDI DSM-IV 9
Mundt et al7*‡ Chile Americas Female Random 153 1·0 Field worker CIDI DSM-IV 8
Mundt et al29 Chile Americas Male Consecutive 
systematic
229 7·0 Clinical psychologist MINI DSM-IV 10
Mundt et al29 Chile Americas Female Consecutive 198 7·0 Clinical psychologist MINI DSM-IV 9
Naidoo and Mkize40 South Africa Africa Male Stratified 
systematic 
random
193 22·8 Psychiatrist MINI Not stated 7
Nanéma et al25‡ Burkina Faso Africa Male Systematic 
random
419 2·8 Medical student MINI ICD-10 6
Ndetei et al41†‡ South Sudan Africa Mixed Population 192 53·5 Clinical psychologist MINI-Plus ICD-10 5
Niriella et al42 Sri Lanka Southeast Asia Male Random 325 0·8 Trained research 
assistant
Not stated ICD-10 7
Niriella et al42 Sri Lanka Southeast Asia Female Random 68 0·8 Trained research 
assistant
Not stated ICD-10 6
Pondé et al26 Brazil Americas Male Random; 
population
497 4·0 Medical student MINI-Plus DSM-IV 7
Salifou et al43‡ Togo Africa Female Population 61 9·0 Psychiatrist, 
psychologist
Clinical 
Interview
DSM-V 7
Silva et al28‡ Brazil Americas Male Consecutive 466 3·0 Not stated MINI-Plus DSM-IV 7
Silva et al28‡ Brazil Americas Female Consecutive 91 3·0 Not stated MINI-Plus DSM-IV 6
Zamzam and Hatta37† Malaysia Western Pacific Female Population 80 3·6 Trainee psychiatrist CIDI Not stated 7
CIDI=Composite International Diagnostic Interview. DSM=Diagnostic and Statistical Manual of Mental Disorders. ICD=International Classification of Diseases. IPIS=Indian Psychiatric Interview Schedule. 
MINI=Mini-International Neuropsychiatric Interview. PSE=Present State Examination. SCID=Structured Clinical Interview for DSM Disorders. *Results are based on 1 year coverage. †Study reported separate rate 
for schizophrenia. ‡Authors provided additional data. 
Table 1: Studies reporting prevalence estimates for severe mental disorders or substance use disorders in prison populations of low-income and middle-income countries
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the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
We identified 23 publications with 30 samples published 
between 1997 and 2018 (figure 1). They provided data 
from 13 different LMICs: Burkina Faso,25 Brazil,6,26–28 
Chile,7,29 Egypt,30 India,31–35 Iran,36 Malaysia,37 Nigeria,38,39 
South Africa,40 South Sudan,41 Sri Lanka,42 Togo,43 and 
Turkey.44,45 Five studies were written in languages other 
than English: two in French,25,43 two in Portuguese,27,28 and 
one in Turkish.45 Of 14 527 imprisoned individuals, 
85% were men and the weighted mean age was 31·8 years. 
Approximately 93% of the participants were prisoners in 
wards, while 7% at arrival to prison (table 1; appendix).
1 year prevalence rates of psychotic disorders were 
reported in 22 samples involving 13 135 individ -
uals.6,7,25,26,28–37,40,41,45 The random-effects pooled prevalence 
was 6·2% (95% CI 4·0–8·6) with very high between-
sample heterogeneity (I²=96; p<0·001; figure 2). We 
noted 15·8 times (95% CI 8·7–28·9) higher rates of 
non-affective psychosis than in the general population 
(table 2). Meta-regression indicated lower prevalence 
of psychosis in studies with smaller sample sizes 
(β=–0·076; p=0·004), decreasing rates with longer 
time spent in prison (β=–0·146; p<0·001), and higher 
estimates in samples recruited at prison intake 
(β=0·186; p<0·001). In the multivariate model, only the 
elevated prevalence of admission samples remained 
significant (β=0·138; p=0·026; appendix). The pooled 
prevalence of psychosis was 3·9% (95% CI 2·8–5·8) in 
non-admission samples. For this subgroup, prevalence 
rates ranged from 0·7% to 10·4% with substantial 
heterogeneity (I²=87; p<0·001) and were slightly higher 
in male (4·3%; 95% CI 2·9–6·0) than in female 
populations (2·5%; 1·5–3·7; data not shown). In the 
four admission samples,28,29 the prevalence varied 
between 8·6% and 26·6%.
We identified 26 samples reporting 1 year prevalence 
of major depression (n=13 452).6,7,25,26,28–37,39–41,43–45 The pooled 
1 year prevalence was 16·0% (95% CI 11·7–20·8) with 
substantial heterogeneity (I²=98%; p<0·001; figure 2), 
indicating 6·0 times (95% CI 4·4–8·0) higher rates than 
in the general population (table 2). Meta-regression found 
increased prevalence of major depression at admission 
(β=0·199; p=0·005) and lower estimates in larger samples 
(β=–0·116; p=0·039), of which only higher prevalence at 
prison intake remain significant in the multivariate 
model (β=0·168; p=0·017; appendix). The pooled estimate 
of major depression in non-admission samples was 
13·2% (95% CI 9·5–17·4). For these individuals, prev-
alence varied from 1·0% to 32·0%, with very high 
heterogeneity (I²=97%; p<0·001), and averaged 13·8% 
(95% CI 9·7–18·4) in men and 15·2% (9·2–22·4) in 
women. At prison intake,28,29 the estimates ranged be-
tween 13·7% and 54·1%.
Figure 2: Random-effects meta-analyses of 1-year prevalence studies reporting psychotic disorders (A) and 
major depression (B) in prison populations in low-income and middle-income countries
*Samples were recruited at intake to prison.
 13·7 (10·9–17·2)
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 14·1 (9·8–19·7)
 1·0 (0·6–1·6)
 16·0 (11·7–20·8)
Prevalence 
rate (95% CI)
Weight
(%)
WHO 
region
n/N
Male samples
Silva et al28*
Mundt et al29*
Nanéma et al25
Naidoo and Mkize40
Andreoli et al6
Pondé et al26
Mundt et al7
Assadi et al36
Kaya et al45
Math et al34
Goyal et al32
Kumar and Daria33
Ayirolimeethal et al31
Subtotal (I2=97%, p <0·001)
Female samples
Silva et al28*
Mundt et al29*
Andreoli et al6
Mundt et al7
Joshi et al35
Ayirolimeethal et al31
Zamzam and Hatta37
Subtotal (I2=88%, p <0·001)
Mixed samples
Ndetei et al41
El-Gilany et al30
Overall (I2=96%, p <0·001)
 124/466
 51/229
 21/419
 12/193
 56/1192
 39/497
 6/855
 15/351
 16/305
 116/5024
 13/500
 8/118
 16/222
 23/91
 17/198
 21/617
 2/153
 2/50
 2/33
 1/80
 20/192
 27/1350
Americas
Americas
Africa
Africa
Americas
Americas
Americas
Eastern Mediterranean
Europe
Southeast Asia
Southeast Asia
Southeast Asia
Southeast Asia
Americas
Americas
Americas
Americas
Southeast Asia
Southeast Asia
Western Pacific
Africa
Eastern Mediterranean
 4·85
 4·63
 4·82
 4·55
 4·99
 4·86
 4·95
 4·77
 4·73
  5·06
 4·86
 4·27
 4·61
 61·95
 4·08
 4·56
 4·90
 4·43
 3·52
 3·04
 3·97
 28·51
 
 
 4·55
 5·00
 100·00
 26·6 (22·8–30·8)
 22·3 (17·4–28·1)
 5·0 (3·3–7·5)
 6·2 (3·6–10·6)
 4·7 (3·6–6·1)
 7·8 (5·8–10·5)
 0·7 (0·3–1·5)
 4·3 (2·6–6·9)
 5·2 (3·3–8·4)
 2·3 (1·9–2·8)
 2·6 (1·5–4·4)
 6·8 (3·5–12·8)
 7·2 (4·5–11·4)
 6·6 (3·7–10·2)
 25·3 (17·5–35·1)
 8·6 (5·4–13·3)
 3·4 (2·2–5·1)
 1·3 (0·4–4·6)
 4·0 (1·1–13·5)
 6·1 (1·7–19·6)
 1·3 (0·2–6·7)
 5·7 (1·9–11·0)
 10·4 (6·8–15·5)
 2·0 (1·4–2·9)
 6·2 (4·0–8·6)
Male samples
Silva et al28*
Mundt et al29*
Nanéma et al25
Majekodunmi et al39
Naidoo and Mkize40
Pondé et al26
Andreoli et al6
Mundt et al7
Assadi et al36
Boşgelmez et al44
Kaya et al45
Ayirolimeethal et al31
Math et al34
Kumar and Daria33
Goyal et al32
Subtotal (I2=98%, p <0·001)
Female samples
Silva et al28*
Mundt et al29*
Salifou et al43
Andreoli et al6
Mundt et al7
Boşgelmez et al44
Ayirolimeethal et al31
Joshi et al35
Zamzam and Hatta37
Subtotal (I2=91%, p <0·001)
Mixed samples
Ndetei et al41
El-Gilany et al30
Overall (I2=98%, p <0·001)
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Findings of our sensitivity analysis on non-admission 
samples showed no significant variation in prevalence rates 
or prevalence ratios for severe mental illness in samples 
reporting only 6 month estimates. The prevalence ratio for 
samples reporting solely schizophrenia was 7·9 (95% CI 
4·9–12·7) compared with the general population (appendix). 
For substance use disorders, we considered admission 
and non-admission samples separately because the 
former were likely to be higher and more comparable to 
the literature coming from HIC.8 At prison intake,28,29 the 
1 year prevalence of alcohol use disorders ranged from 
13·6% to 42·3%, and for drug use disorders estimates 
were between 27·3% and 68·1%.
We identified 12 non-admission samples reporting 
1 year prevalence of alcohol use disorders 
(n=9491).6,7,25,26,34–37,41,43 The pooled prevalence was 3·8% 
Study Sex Psychotic disorders Major depression
Population 
prevalence
Prevalence ratio Population 
prevalence
Prevalence ratio
Estimate 95% CI Estimate 95% CI
Africa
Burkina Faso Nanéma et al25 Men 0·12 41·67* 27·48–63·28 1·48 19·05 16·35–22·20
Nigeria Majekodunmi et al39 Men ·· ·· ·· 1·74 18·16 14·78–22·32
South Africa Naidoo and Mkize40 Men 0·19 24·74* 13·10–46·70 2·21 4·71 3·11–7·12
South Sudan Ndetei et al41 Mixed 0·13 32·31 16·44–63·50 1·97 7·16 5·05–10·15
Togo Salifou et al43 Women ·· ·· ·· 2·45 12·69 8·74–18·44
Americas
Brazil Andreoli et al6 Men 0·22 8·64 5·74–12·99 1·95 3·54 2·87–4·36
Brazil Pondé et al26 Men 0·22 27·27* 19·26–38·63 2·02 2·97 2·10–4·21
Brazil Silva et al28† Men 0·22 120·91* 103·98–140·60 1·95 7·03 5·59–8·82
Brazil Andreoli et al6 Women 0·20 7·50 3·96–14·22 4·26 4·37 3·70–5·15
Brazil Silva et al28† Women 0·20 126·50* 88·87–180·07 4·26 6·46 4·62–9·01
Chile Mundt et al7 Men 0·23 3·04* 1·37–6·76 2·13 2·86 2·20–3·73
Chile Mundt et al29† Men 0·23 96·96* 76·10–123·52 2·16 25·05 22·23–28·22
Chile Mundt et al7 Women 0·21 6·19* 1·56–24·63 3·79 2·93 1·87–4·59
Chile Mundt et al29† Women 0·22 39·09* 24·82–61·57 3·61 12·02 10·25–14·10
Eastern Mediterranean
Iran Assadi et al36 Men 0·18 11·11 5·34–23·11 3·15 8·86 7·49–10·48
Egypt El–Gilany et al30 Mixed 0·18 4·44 2·45–8·05 2·28 0·42 0·25–0·72
Europe
Turkey Boşgelmez et al44 Men ·· ·· ·· 2·05 6·49 2·60–16·18
Turkey Kaya et al45 Men 0·19 5·26* 1·72–16·08 2·02 10·88 8·80–13·44
Turkey Boşgelmez et al44 Women ·· ·· ·· 3·66 2·73 0·93–7·99
Southeast Asia
India Ayirolimeethal et al31 Men 0·24 28·33* 17·41–46·11 1·82 1·48 0·67–3·27
India Goyal et al32 Men 0·23 1·74 0·44–6·94 1·91 8·48 6·95–10·35
India Kumar and Daria33 Men 0·23 14·78 5·65–38·68 1·90 8·47 5·61–12·79
India Math et al34 Men 0·24 4·58 3·53–5·96 1·82 5·00 4·58–5·46
India Ayirolimeethal et al31 Women 0·23 13·04* 1·87–90·78 2·64 1·14 0·16–7·91
India Joshi et al35 Women 0·23 17·39* 4·47–67·62 2·62 12·21 8·15–18·30
Western Pacific
Malaysia Zamzam and Hatta37 Women 0·26 5·00 0·74–33·75 1·57 4·78 2·21–10·31
Pooled prevalence ratio I ·· Total I²=97% 15·83 8·68–28·87 I²=98% 5·95 4·41–8·03
Pooled prevalence ratio II 
(non–admission samples) 
·· Men I²=93% 11·10 6·05–20·37 I²=97% 6·30 4·35–9·13
Pooled prevalence ratio II 
(non–admission samples) 
·· Women I²=0% 8·26 5·03–13·58 I²=89% 5·26 3·10–8·93
Pooled prevalence ratio II 
(non–admission samples) 
·· Total I²=90% 10·68 6·68–17·06 I²=97% 5·31 3·94–7·19
*Admission samples.†Sample reported non-affective psychotic disorders; otherwise, prevalence of schizophrenia was extracted. Population prevalence refers to the 
sex-specific, country-specific, and year-specific rates in the general population retrieved from the Global Burden of Disease database 2016.
Table 2: Prevalence ratios of severe mental illness in prison populations in low-income and middle-income countries
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Figure 3: Random-effects meta-analysis of prevalence studies reporting alcohol use disorders (A) and drug use disorders (B) in prison populations in 
low-income and middle-income countries 
NA=not applicable. 
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(95% CI 1·2–7·6; figure 3), 2·4 times higher than 
(1·1–5·2) in the general population (table 3). The 
estimates ranged from 0·0% to 18·0% (I²=98%, 
p<0·001), and were similar for men (3·7%, 95% CI 
0·5–9·4) and women (4·4%, 1·5–8·4; figure 3). Meta-
regression indicated geographical variation, with 
elevated prevalence in the southeast Asian region in 
comparison to the eastern Mediterranean region 
(β=0·140; p=0·038; appendix). We recorded higher 
estimates in lower quality studies (β=–0·024; p=0·001), 
which could be attributed to two lower quality studies 
with high prevalence esti mates from the southeast 
Asian region.34,35 The lifetime prevalence rate of alcohol 
use disorders (eight samples; n=8566)6,26,32,34,36,37 was 
27·6% (95% CI 18·6–37·7; men: 32·2%, 22·3–43·0, 
and women: 15·2%, 12·6–18·0) and varied between 
13·8% and 43·4% (I²=99%, p<0·001; figure 3). The 
small number of samples precluded further analyses.
For the 11 samples reporting 1 year prevalence rates of 
drug use disorders (n=4670),6,7,25,26,35–38,43 the pooled 
estimate was 5·1% (95% CI 2·9–7·8), 5·3% (2·5–9·0) in 
male and 5·0% (1·6–9·8) in female samples—
ie, 6·1 times (95% CI 4·0–9·4) higher than in the general 
population (table 3). The 1 year prevalence of drug use 
disorders ranged from 1·3% to 11·3% (I²=92%; p<0·001; 
figure 3). Findings of meta-regression did not show any 
signifi cant explanation for heterogeneity (appendix). 
Studies on lifetime prevalence of drug use disorders 
(11 samples; n=9246)6,26,27,32,34,36,37,42 indicated a pooled 
estimate of 30·6% (95% CI 18·1–44·8; men: 27·2%, 
95% CI 12·1–45·7, and women: 36·7%, 95% CI 
25·9–48·2), ranging be tween 6·4% and 75·5% (I²=99%; 
p<0·001; figure 3). Meta-regression results showed 
geographical variation between samples with elevated 
prevalence in the eastern Mediterranean in comparison 
to the European region (β=0·627; p=0·019; appendix). 
Study Sex Alcohol use disorders Drug use disorders
Population 
prevalence
Prevalence ratio Population 
prevalence
Prevalence ratio
Estimate 95% CI Estimate 95% Cl
Africa
Burkina Faso Nanéma et al25 Men 1·00 4·50 2·90–7·00 0·39 11·03 7·02–17·32
Nigeria Adesanya et al38 Men ·· ·· ·· 0·37 7·57 4·23–13·53
South Sudan Ndetei et al40 Mixed 1·11 0·90 0·22–3·68 ·· ·· ··
Togo Salifou et al43 Women 0·96 5·10 1·69–15·42 0·30 11·00 2·83–42·80
Americas
Brazil Andreoli et al6 Men 4·28 0·44 0·30–0·67 1·30 1·00 0·61–1·64
Brazil Pondé et al26 Men 4·29 0·70 0·42–1·15 1·27 7·01 5·29–9·28
Brazil Silva et al28* Men 4·28 9·88 8·89–10·99 1·30 36·31 32·98–39·97
Brazil Andreoli et al6 Women 1·38 1·74 1·05–2·88 0·72 2·22 1·20–4·13
Brazil Silva et al28* Women 1·38 23·91 17·84–32·05 0·72 68·75 55·87–84·61
Chile Mundt et al7 Men 3·78 1·32 0·99–1·77 1·38 4·86 3·78–6·24
Chile Mundt et al29* Men 3·60 9·33 7·78–11·20 1·44 47·29 43·27–51·68
Chile Mundt et al7 Women 1·46 1·78 0·68–4·70 0·78 8·33 4·57–15·20
Chile Mundt et al29* Women 1·40 9·71 6·84–13·80 0·80 34·13 27·18–42·84
Eastern Mediterranean
Iran Assadi et al36 Men 0·64 0·22 0·01–3·58 2·50 4·44 3·30–5·97
Southeast Asia
India Math et al34 Men 2·03 6·90 6·44–7·39 ·· ·· ··
India Joshi et al35 Women 0·43 41·86 23·17–75·64 0·37 16·22 5·41–48·58
Western Pacific
Malaysia Zamzam and 
Hatta37
Women 0·32 7·81 1·99–30·70 0·54 20·83 11·26–38·56
Pooled prevalence ratio 
(non–admission samples) 
·· Men I²=99% 1·40 0·45–4·36 I²=92% 4·85 2·93–8·04
Pooled prevalence ratio 
(non–admission samples) 
·· Women I²=94% 5·54 1·23–24·92 I²=86% 8·98 3·62–22·27
Pooled prevalence ratio 
(non–admission samples) 
·· Total I²=97% 2·43 1·12–5·24 I²=89% 6·11 3·98–9·39
*Admission samples. Population prevalence refers to the sex-specific, country-specific, and year-specific rates in the general population retrieved from the Global Burden of 
Disease database 2016.
Table 3: Prevalence ratios of substance use disorders in prison populations in low-income and middle-income countries
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Egger’s test of asymmetric funnel plot indicated small 
sample bias for psychotic illnesses (p=0·027), current 
alcohol use disorders (p=0·025) and for lifetime drug use 
disorders (p=0·013) in non-admission studies. After 
excluding the study with the lowest quality score, which 
also had the largest sample size,34 evidence for publication 
bias did not remain significant (appendix).
Discussion
Our findings suggest that incarcerated individuals in 
LMICs have a higher prevalence of psychiatric disorders 
than the general population and that rates at arrival to 
prison are elevated. Furthermore, our results show that 
there is geographical variation in the prevalence of 
substance use disorders.
The study had several limitations. Our findings are 
based on only 13 of more than 100 LMICs, and we could 
not identify any studies meeting our criteria from China, 
which has the largest prison population among LMICs. 
Additionally, there was high heterogeneity between 
studies. This was not unexpected as the included countries 
are substan tially different in terms of their criminal and 
health-care systems.
Consistent with systematic reviews from prisoners in 
HICs,4,8 our findings provide evidence for higher prev-
alence of psychiatric disorders in incarcerated people than 
in the general population.46,47 Imprisoned individuals often 
have a low socioeconomic background, belong to minority 
groups, and have histories of childhood victimisation 
and substance abuse, which make them vulnerable to 
psychiatric disorders.9,48 While in prison, poor living 
conditions,3 physical assault20 and psychological abuse5 
can further contribute to mental health disorders.
Although general population reviews indicate a lower 
prevalence of schizophrenia47 and major depression46 in 
LMICs than in HICs, we did not find this among 
prisoners.4 A high prevalence of severe mental illness in 
prisoners in LMICs could relate to poorly developed 
community mental health-care systems that do not yet 
reach socially deprived and marginalised populations in 
these countries. Human rights violations among indi-
viduals with mental health problems during imprison-
ment, especially for those with psychotic conditions, 
have been reported to be more common in poorly 
resourced settings.5
Upon arrival to prison, we found similar 1 year prevalence 
estimates of alcohol and drug use disorders as those 
reported for individuals in HICs.8 These are comparable to 
lifetime rates and provide information about the substance 
use problems before imprisonment. However, the 
estimates on current prevalence among non-intake 
samples represent the average disease burden during 
imprisonment, which might be relevant for service 
planning. Even though addictive substances are available 
in most prisons in LMICs,48 the prevalence of substance 
use disorders for this population is substantially lower 
during imprisonment than for the same population while 
outside of prison. We found regional variation in the 
prevalence of substance use disorders, possibly linked to 
regional differences of the substances used.48 The highest 
rates of alcohol use disorders were found in studies from 
India,34,35 while the highest rate for drug use disorders was 
reported in a study from Iran.36 While lower rates of 
substance use disorders in women are found in the general 
population,46 this is typically not the case for prison 
populations. The rates of substance use disorders among 
prisoners start considerably higher than population 
comparisons independent of sex, likely due to substance 
use being a major driver of criminality.49 In HICs, 
incarcerated women have similar rates of alcohol use 
disorders as incarcerated men and a higher prevalence of 
illicit drug use disorders than men.8 This difference can be 
explained by lower rates of female incarceration and hence 
women in prison being a more selected group of high-risk 
individuals with elevated rates of substance use problems. 
Admission studies indicated higher rates of psychosis 
and major depression at arrival to prison compared with 
investigations that included prisoners at later stages of 
imprisonment, which is consistent with longitudinal 
studies from HICs reporting high rates of psychiatric 
disorders at intake to prison.50,51 However, this finding 
was based on only two intake studies conducted in Latin 
American countries. The very high prevalence of severe 
mental illness at intake to prison in those countries could 
be linked to the use of cocaine products before impris-
onment.29,48,51 There are several possible explanations for 
lower rates of mental health symptoms at later stages of 
imprisonment in spite of the harsh conditions of LMICs 
prisons including: reduced access to substances during 
imprisonment, protection or removal from adverse social 
environments outside of prisons, development of coping 
mechanisms,50 some availability of treatment services, 
and diversion of mentally ill prisoners.3 However, the 
literature points to substantial unmet health-care needs.3
Our findings have several implications. First, the low 
number of included samples emphasises the paucity of 
epidemiological investigations in LMICs. Although more 
than 100 high quality samples provide reliable evidence of 
psychiatric disorders in prisons in HICs,20 we found only 
30 samples from a much more diverse group of countries. 
Further evidence is needed to adequately plan interventions 
for prisoners with mental disorders in LMICs, especially 
from regions underrepresented in research such as central 
and east Asia, and Central America. Second, cost-effective 
interventions and scalable treatments should be prioritised, 
either by adapting existing programmes from HICs to 
local conditions or by developing new programmes on a 
large scale (eg, interventions at the transition from prison 
to the community for individuals with mental illness).52,53 
Effective psychological treatments in prison settings have 
been reported for HICs52 and some might be trans ferable 
to resource-poor settings. Furthermore, com munity 
interventions in LMICs, such as enhancing health literacy,54 
using digital technologies in prevention,55 as well as 
Articles
e470 www.thelancet.com/lancetgh   Vol 7   April 2019
treatments of severe mental disorders,56 have shown 
promising ways of addressing the mental health treatment 
gap. Some of these interventions could also be used 
to prevent and treat psychiatric disorders in prison 
populations.
Finally, imprisonment could present an opportunity to 
treat people with mental health and substance use 
problems who otherwise would be difficult to reach for 
health services;4 however, neither the funding nor quali-
fied staff for such treatments are usually available in 
prisons. National governments in LMICs should move 
the responsibility for prison health care from prison 
administrations to the national health services.5 In 
conclusion, our findings of high prevalence estimates for 
major mental health and substance use disorders among 
prisoners in LMICs present an impor tant global mental 
health challenge, indicate a treatment gap, and might 
raise concerns about human rights violations.
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